Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P53 versus Ocrevus in relapsing-remitting multiple sclerosis
2022-501622-37-00Phase 3Authorised
- Sponsor
- Celltrion
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing CT-P53 with Ocrevus (2 arms). Primary endpoints: Area under the concentration-time curve from time zero to Week 2 and Area under the concentration-time curve from Week 2 to Week 24. Planned start Jan 2024; status: authorised.
02
Drugs
CT-P53ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2022-501622-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501622-37-00.